159 related articles for article (PubMed ID: 5358212)
1. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Cancer Res; 1969 Nov; 29(11):1944-51. PubMed ID: 5358212
[No Abstract] [Full Text] [Related]
2. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
Kingra GS; Comis R; Olson KB; Horton J
Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
[No Abstract] [Full Text] [Related]
3. Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide.
Loo TL; Luce JK; Jardine JH; Frei E
Cancer Res; 1968 Dec; 28(12):2448-53. PubMed ID: 5728154
[No Abstract] [Full Text] [Related]
4. Combination phase 1-II study of imidazole carboxamide (NCS45388).
Wagner DE; Ramirez G; Weiss AJ; Hill G
Oncology; 1972; 26(2):310-6. PubMed ID: 5049924
[No Abstract] [Full Text] [Related]
5. Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide to 4(5)-aminoimidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Biochem Pharmacol; 1970 Jun; 19(6):2043-51. PubMed ID: 5513972
[No Abstract] [Full Text] [Related]
6. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
Luce JK; Thurman WG; Isaacs BL; Talley RW
Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
[No Abstract] [Full Text] [Related]
7. Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.
Gerner RE; Moore GE
Cancer Chemother Rep; 1973 Feb; 57(1):83-4. PubMed ID: 4704107
[No Abstract] [Full Text] [Related]
8. Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda.
Vogel CL; Comis R; Ziegler JL; Kiryabwire JW
Cancer Chemother Rep; 1971 Apr; 55(2):143-9. PubMed ID: 5118684
[No Abstract] [Full Text] [Related]
9. Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma.
Bruckner HW; Mokyr MB; Mitchell MS
Cancer Res; 1974 Jan; 34(1):181-3. PubMed ID: 4588545
[No Abstract] [Full Text] [Related]
10. [Are combinations more effective than monotherapy in the matter of antiocancer chemotherapy?].
Horton J; Olson K
Poumon Coeur; 1968; 24(1):59-62. PubMed ID: 4968016
[No Abstract] [Full Text] [Related]
11. Postsurgical adjuvant chemotherapy: a review.
Diekamp U; Lad TE; McGuire WP
Surg Annu; 1981; 13():31-52. PubMed ID: 7025285
[No Abstract] [Full Text] [Related]
12. [Results of a phase I clinical trial of "theraphthal + ascorbic acid" catalytic system].
Garin AM; Gorbunova VA; Gershanovich ML; Manziuk LV; Borodkina AG; Breder VV; Karmanovskaia OB; Zubrikhina GN; Madzhuga AV; Zimakova NI; Trapeznikov NN
Vopr Onkol; 2001; 47(6):676-9. PubMed ID: 11826487
[TBL] [Abstract][Full Text] [Related]
13. Disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, a new antitumor agent.
Housholder GE; Loo TL
J Pharmacol Exp Ther; 1971 Nov; 179(2):386-95. PubMed ID: 5133607
[No Abstract] [Full Text] [Related]
14. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
Sava G; Giraldi T; Lassiani L; Nisi C
Cancer Res; 1984 Jan; 44(1):64-8. PubMed ID: 6690062
[TBL] [Abstract][Full Text] [Related]
15. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma.
Moertel CG; Reitemeier RJ; Hahn RG; Schutt AJ
Cancer Chemother Rep; 1970 Dec; 54(6):471-3. PubMed ID: 4946016
[No Abstract] [Full Text] [Related]
16. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
Stolinsky DC; Bogdon DL; Solomon J; Bateman JR
Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
[No Abstract] [Full Text] [Related]
17. Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally.
Vogel CL; DeVita VT; Denham C; Foley HT; Field RB; Carbone PP
Cancer Chemother Rep; 1971 Apr; 55(2):159-65. PubMed ID: 5118685
[No Abstract] [Full Text] [Related]
18. Clinical evaluation of 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in malignant melanoma and other neoplasms: comparison of twice-weekly and daily administration schedules.
Gottlieb JA; Serpick AA
Oncology; 1971; 25(3):225-33. PubMed ID: 5153084
[No Abstract] [Full Text] [Related]
19. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
Carter SK; Friedman MA
Eur J Cancer (1965); 1972 Feb; 8(1):85-92. PubMed ID: 4552317
[No Abstract] [Full Text] [Related]
20. A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC63878).
Burke PJ; Owens AH; Colsky J; Shnider BI; Edmonson JH; Schilling A; Brodovsky HS; Wallace HJ; Hall TC
Cancer Res; 1970 May; 30(5):1512-5. PubMed ID: 5426952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
